The Alteration of Prostaglandin E2 Levels in Patients with Brain Tumors before and after Tumor Removal
- 190 Downloads
Background. Both experimental and human tumors often synthesize high levels of prostaglandins, most notably prostaglandin E2 (PGE2). This compound may play an important role in tumor growth and immunosuppression. Little is known of the production of PGE2 by brain tumors. The present study was designed to investigate the levels of PGE2 in the plasma of human brain tumors before and after tumor removal.
Methods. The plasma PGE2 levels of brain tumors before and after tumor removal were measured by high-performance liquid chromatography (HPLC).
Results. There is a significantly high concentration of PGE2 in malignant brain tumor before tumor removal. Significantly decrease of PGE2 concentration after total removal of the tumor was found both in the malignant and benign brain tumor groups (P=0.0001 and P=0.0039 respectively). However, compared to the control group, only malignant brain tumor showed a significant decrease of PGE2 concentration after tumor removal (P=0.0009).
Conclusion. Our study demonstrates the malignant brain tumor synthesized higher relative proportions of PGE2 and surgical removal of the brain tumor can reduce the production of PGE2.
Unable to display preview. Download preview PDF.
- 1.Tada M, De Tribolet N: Recent advances in immunobiology of brain tumors. J Neuro-Oncol 17: 261-271, 1993Google Scholar
- 2.Mahaley MS, Brooks WH, Bigner DD, Roszman TL: Immunobiology of primary intracranial tumors. I. Studies of the cellular and humoral general immune competence of brain tumor patient. J Neurosurg 46: 467, 1997Google Scholar
- 3.Brooks WH, Caldwell HD, Mortara RH: Immune responses in patients with gliomas. Surg Neurol 2: 419, 1974Google Scholar
- 4.Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immnol Today 12: 370-374, 1991Google Scholar
- 5.Couldwell WT, Dore-Duffy P, Apuzzo MLJ, Antel JP: Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 33: 89-96, 1991Google Scholar
- 6.Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2 mediated effects. J Immunol 132: 1837-1844, 1984Google Scholar
- 7.Lauro GM, Di Lorenzo N, Grossi M, Maleci A, Guidetti B: Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol 69: 278-282, 1986Google Scholar
- 8.Roszman TL, Brooks WH, Elliott LH: Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. J Neurosurg 67: 874-879, 1987Google Scholar
- 9.Miescher S, Whiteside TL, de Tribolet N, Von Fliedner V: In situ characterization, clonogenic potential and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68: 438-448, 1988Google Scholar
- 10.Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-B1, B2 and B3 by glioblastoma cells, astrocytes and microglia. J Immunol 148: 1404-1410, 1992Google Scholar
- 11.Sporn MB, Roberts AB: Transforming growth factor-B: recent progress and new challenges. J Cell Biol 119: 1017-1021, 1992Google Scholar
- 12.Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J: Negative regulation of G1 in mammalian cells: inhibition of cyain E-dependent kinace by TGF-B. Science 260: 536-539, 1993Google Scholar
- 13.Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW: Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1B. J Immunol 150: 2659-2667, 1993Google Scholar
- 14.Betz M, Fox BS: Prostaglandin E2 inhibits production of TH1 lymphokines but not of Th2 lymphokines. J Immunol 146: 108, 1991Google Scholar
- 15.Hilkens CM, Vermeulen H, Joost Van Neerven: Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol 25: 59, 1995Google Scholar
- 16.Krstulovic AM: Investigations of catecholamine metabolism using HPLC. J Chromatogr 229: 1-34, 1982Google Scholar
- 17.Holly JMP, Makin HLJ: The estimation of catecholamines in human plasma. Anal Biochem 126: 257-274, 1983Google Scholar
- 18.Anagnostopoulos-Schleep J, Schlegel W, Krähling KH, König HJ: Prostaglandins F2á and E2 as possible mediatiors of peritumoral brain edema. Adv Neurosurg 16: 243-249, 1988Google Scholar
- 19.Köko¢glu E, Tüter Y, Sandikci KS, Yazici Z, Ulako¢glu E2, Sönmez H, Özyurte E: Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors. Cancer Lett 132: 17-21, 1998Google Scholar
- 20.Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P, Paoletti P: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49: 1505-1508, 1989Google Scholar
- 21.Cooper C, Jones HG, Weller RO, Walker V: Production of prostaglandins and thromboxane by isolated cells from intracranial tumors. J Neurol Neurosurg Psychiatry 47: 579-584, 1984Google Scholar
- 22.Chouaib S, Robb RJ, Weite K, Dupont B: Analysis of Prostaglandin E2 effect on T lymphocyte activation. J Clin Invest 80: 333-340, 1987Google Scholar
- 23.Eddleston M, Mucke L: Moleculor profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 54: 15-36, 1993Google Scholar
- 24.Goodwin JS: Prostaglandin synthetase inhibitors as immunoadjuvants in treatment of cancer. J Immunopharmacol 2: 397-424, 1980Google Scholar